W. Hagmann

发表

A direct functionalization of tertiary alkyl bromides with O-, N-, and C-nucleophiles

P. Váchal, Joan M. Fletcher, W. Hagmann, 2007 .

[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor

Patrick Dupont, John A Wagner, Koen Van Laere, 2007, Proceedings of the National Academy of Sciences.

Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor*

M. Maccoss, C. Hacker, S. D. de Laszlo, 1999, The Journal of Biological Chemistry.

Inhibition of interleukin-1β converting enzyme by N-acyl-aspartyl aryloxymethyl ketones

M. Maccoss, N. Thornberry, E. Peterson, 1995 .

N-isonicotinoyl-(L)-4-aminophenylalanine derivatives as tight binding VLA-4 antagonists.

W. Hagmann, Kashmira Shah, R. Mumford, 2003, Bioorganic & medicinal chemistry letters.

N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.

M. Maccoss, S. D. de Laszlo, Bing Li, 2002, Bioorganic & medicinal chemistry letters.

N-aryl 2,6-dimethoxybiphenylalanine analogues as VLA-4 antagonists.

W. Hagmann, T. Kamenecka, R. Mumford, 2002, Bioorganic & medicinal chemistry letters.

Substituted tetrahydrofuroyl-1-phenylalanine derivatives as potent and specific VLA-4 antagonists.

M. Maccoss, W. Hagmann, John A. Schmidt, 2002, Bioorganic & medicinal chemistry letters.

The discovery of sulfonylated dipeptides as potent VLA-4 antagonists.

M. Maccoss, S. D. de Laszlo, J. Fenyk-Melody, 2001, Bioorganic & medicinal chemistry letters.

Amidines as amide bond replacements in VLA-4 antagonists.

M. Maccoss, S. D. de Laszlo, W. Hagmann, 2004, Bioorganic & medicinal chemistry letters.

A Small Molecule α4β1/α4β7 Antagonist Differentiates between the Low-Affinity States of α4β1 and α4β7: Characterization of Divalent Cation Dependence

S. D. de Laszlo, P. Detmers, C. Raab, 2003, Journal of Pharmacology and Experimental Therapeutics.

Substituted 3-amino biaryl propionic acids as potent VLA-4 antagonists.

M. Maccoss, W. Hagmann, K. Lyons, 2002, Bioorganic & medicinal chemistry letters.

α4β7/α4β1Dual Integrin Antagonists Block α4β7-Dependent Adhesion under Shear Flow

S. E. D. Laszlo, B. Pikounis, P. Detmers, 2002 .

ChemInform Abstract: The Discovery of Sulfonylated Dipeptides as Potent VLA-4 Antagonists.

W. Hagmann, 2010 .

Specific and dual antagonists of α4β1 and α4β7 integrins

M. Maccoss, W. Hagmann, L. Lin, 2002 .

The discovery of acylated beta-amino acids as potent and orally bioavailable VLA-4 antagonists.

M. Maccoss, S. D. de Laszlo, J. Fenyk-Melody, 2002, Bioorganic & medicinal chemistry letters.

Dual Integrin Antagonists Block 4 7-Dependent Adhesion under Shear Flow

S. E. D. Laszlo, B. Pikounis, P. Detmers, 2002 .

Identification of unique VLA-4 antagonists from a combinatorial library.

S. D. de Laszlo, Bing Li, W. Hagmann, 2002, Bioorganic & medicinal chemistry letters.

Deprotection of N-tert-butoxycarbonyl (Boc) groups in the presence of tert-butyl esters

S. E. D. Laszlo, W. Hagmann, T. Kamenecka, 2000 .

The discovery and potential of N-sulfonylated dipeptide VLA-4 antagonists.

W. Hagmann, 2004, Current topics in medicinal chemistry.

Comparison of the structure of human recombinant short form stromelysin by multidimensional heteronuclear NMR and X-ray crystallography

Paul R. Gooley, Melinda G. Axel, J. W. Becker, 1996, Journal of biomolecular NMR.

Design, synthesis and biological evaluation of indane derived GPR40 agoPAMs.

A. Howard, R. Nargund, W. Hagmann, 2019, Bioorganic & medicinal chemistry letters.

Design and Synthesis of Novel, Selective GPR40 AgoPAMs.

A. Howard, R. Nargund, W. Hagmann, 2017, ACS medicinal chemistry letters.

GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production

K. Knagge, R. Myers, W. Hagmann, 2017, PloS one.

In vivo effects of stromelysin on the composition and physical properties of rabbit articular cartilage in the presence and absence of a synthetic inhibitor.

L. Bonassar, E. Frank, M. Lark, 1995, Arthritis and rheumatism.

Use of an antibody against the matrix metalloproteinase-generated aggrecan neoepitope FVDIPEN-COOH to assess the effects of stromelysin in a rabbit model of cartilage degradation.

P. Griffin, W. Hagmann, J. Calaycay, 1995, Arthritis and rheumatism.

Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.

D. Macneil, J. Metzger, D. Macintyre, 2008, European journal of pharmacology.

Cephalosporin antibiotics can be modified to inhibit human leukocyte elastase

K. R. Thompson, W. Hagmann, A. Maycock, 1986, Nature.

Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in Rodents

D. Macintyre, L. V. D. van der Ploeg, L. Shearman, 2007, Journal of Pharmacology and Experimental Therapeutics.

N-aryl-prolyl-dipeptides as potent antagonists of VLA-4.

M. Maccoss, S. D. de Laszlo, Bing Li, 2002, Bioorganic & medicinal chemistry letters.

Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor Agonists.

Yun-ping Zhou, E. Sherer, A. Howard, 2014, ACS medicinal chemistry letters.

The Discovery of Taranabant, a Selective Cannabinoid‐1 Receptor Inverse Agonist for the Treatment of Obesity

W. Hagmann, 2008, Archiv der Pharmazie.

Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists.

J. Chen, L. V. D. van der Ploeg, L. Shearman, 2007, Bioorganic & medicinal chemistry letters.

W. Hagmann, James P. Jewell, L. Lin, 2008, Brain Research.

A comparison of alpha 1-proteinase inhibitor methoxysuccinyl-Ala-Ala-Pro-Val-chloromethylketone and specific beta-lactam inhibitors in an acute model of human polymorphonuclear leukocyte elastase-induced lung hemorrhage in the hamster.

W. Hagmann, J. Doherty, R. Mumford, 1990, The American review of respiratory disease.

Effects of Matrix Metalloproteinases on Cartilage Biophysical Properties in Vitro and in Vivo a

L. Bonassar, E. Frank, A. Grodzinsky, 1994, Annals of the New York Academy of Sciences.

Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.

F. Ujjainwalla, E. Sherer, R. Nargund, 2016, Bioorganic & medicinal chemistry letters.

Pharmacological profile of the substituted beta‐lactam L‐659,286: A member of a new class of human PMN elastase inhibitors

L. Schaeffer, W. Hagmann, A. Maycock, 1989, Journal of cellular biochemistry.

Investigation of Cardiovascular Effects of Tetrahydro-β-carboline sstr3 antagonists.

Margaret S. Wu, M. Reibarkh, Yun-ping Zhou, 2014, ACS medicinal chemistry letters.

CHIRAL SYNTHESIS OF C-CARBOXYALKYL DIPEPTIDE INHIBITORS OF STROMELYSIN-1 (MMP-3)

W. Hagmann, M. Ponpipom, 1999 .

Orally active inhibitors of stromelysin-1 (MMP-3)

M. Maccoss, W. Hagmann, K. Chapman, 1996 .

Phosphinic acid inhibitors of matrix metalloproteinases

W. Hagmann, R. Stein, S. Mills, 1996 .

Inhibition of matrix metalloproteinases by P1 substituted N-carboxyalkyl dipeptides

W. Hagmann, K. Chapman, R. Stein, 1996 .

Proteoglycan-degrading activity of human stromelysin-1 and leukocyte elastase in rabbit joints. Quantitation of proteoglycan and a stromelysin-induced HABR fragment of aggrecan in synovial fluid and cartilage.

W. Hagmann, J. Hale, R. Mumford, 1996, Connective tissue research.

F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist.

W. Hagmann, T. Fong, J. Xiao, 2006, European journal of pharmacology.

Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.

P. Davies, M. Maccoss, C. Raab, 2009, Journal of medicinal chemistry.

Inhibition of matrix metalloproteinases by N-carboxyalkyl dipeptides: Enhanced potency and selectivity with substituted P1′ homophenylalanines

M. Maccoss, W. Hagmann, K. Chapman, 1995 .

Studies on the kinetic and chemical mechanism of inhibition of stromelysin by an N-(carboxyalkyl)dipeptide.

W. Hagmann, K. Chapman, R. Stein, 1994, Biochemistry.

Discovery of substituted (4-phenyl-1H-imidazol-2-yl)methanamine as potent somatostatin receptor 3 agonists.

Yun-ping Zhou, E. Sherer, A. Howard, 2015, Bioorganic & medicinal chemistry letters.

The inhibition of C5a receptor binding by analogs of L-156,602, a cyclic hexadepsipeptide antibiotic

Sumire V. Kobayashi, W. Hagmann, J. Boger, 1992 .

Substituted 2-aminopyridines as inhibitors of nitric oxide synthases.

W. F. Hoffman, Kenny K. Wong, M. Maccoss, 2000, Bioorganic & medicinal chemistry letters.

N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.

M. Maccoss, S. D. de Laszlo, W. Hagmann, 2002, Bioorganic & medicinal chemistry letters.

Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.

L. V. D. van der Ploeg, L. Shearman, D. Marsh, 2006, Journal of medicinal chemistry.

Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.

W. Hagmann, R. Ball, G. Doss, 2008, Journal of medicinal chemistry.

Naphthalenes as inhibitors of myeloperoxidase: Direct and indirect mechanisms of inhibition

R. Egan, W. Hagmann, P. Gale, 1990, Agents and Actions.

A highly active catalyst system for the heteroarylation of acetone

Ping Liu, W. Hagmann, James P. Jewell, 2003 .

Chapter 24. Inhibition of Matrix Metalloproteinases.

J. W. Becker, M. Lark, W. Hagmann, 1996 .

Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding.

W. Hagmann, S. Kobayashi, M. Springer, 1992, Journal of medicinal chemistry.

Mechanism of inhibition of human leucocyte elastase by monocyclic beta-lactams.

M. Maccoss, W. Hagmann, R. Chabin, 1993, Biochemistry.

Mechanism of inhibition of human leukocyte elastase by two cephalosporin derivatives.

W. Hagmann, A. Maycock, J. Doherty, 1992, Biochemistry.

PMN elastases: a comparison of the specificity of human isozymes and the enzyme from other species toward substrates and inhibitors.

M. Lark, W. Hagmann, A. Maycock, 1991, Archives of biochemistry and biophysics.

Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases.

Kenny K. Wong, Ping Chen, M. Maccoss, 2004, Bioorganic & medicinal chemistry letters.

The many roles for fluorine in medicinal chemistry.

W. Hagmann, William K Hagmann, 2008, Journal of medicinal chemistry.

The discovery of small molecule carbamates as potent dual α4β1/α4β7 integrin antagonists

M. Maccoss, W. Hagmann, K. Lyons, 2002 .

Heteroatom directed photoarylation. Synthetic potential of the heteroatom oxygen

W. Hagmann, A. Schultz, R. Lucci, 1978 .

Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques.

W. Hagmann, K. Samuel, Sanjeev Kumar, 2003, Journal of mass spectrometry : JMS.

Potent, orally absorbed glucagon receptor antagonists.

M. Maccoss, C. Hacker, S. D. de Laszlo, 1999, Bioorganic & medicinal chemistry letters.

Substituted imidazoles as glucagon receptor antagonists.

M. Maccoss, S. E. D. Laszlo, S. O'keefe, 2001, Bioorganic & medicinal chemistry letters.

A one-pot synthesis of 3-substituted-5-carbonylmethyl-1,2,4-oxadiazoles from β-keto esters and amidoximes under solvent-free conditions

W. Hagmann, Yan Guo, J. Hale, 2007 .

Preparation of N-carbomethoxyaminopyrroles

W. Hagmann, M. Shen, A. Schultz, 1979 .

Inhibition of human leukocyte elastase by C-2 substituted cephalosporin sulfones

W. Hagmann, A. Maycock, J. Doherty, 1989 .

Inhibition of stromelysin-1 (MMP-3) by peptidyl phosphinic acids

W. Hagmann, R. Stein, R. Harrison, 1994 .

The NMR structure of the inhibited catalytic domain of human stromelysin–1

J. Springer, J. Hermes, P. Gooley, 1994, Nature Structural Biology.

A ‘one-pot’ synthesis of α-1,2,4-oxadiazolo esters from malonic diesters and amidoximes under solvent-free conditions

W. Hagmann, J. Hale, Wu Du, 2006 .

Orally active beta-lactam inhibitors of human leukocyte elastase-1. Activity of 3,3-diethyl-2-azetidinones.

W. Hagmann, J. Hale, S. K. Shah, 1992, Journal of medicinal chemistry.

Prevention of human leukocyte elastase-mediated lung damage by 3-alkyl-4-azetidinones

K. R. Thompson, W. Hagmann, A. Maycock, 1991 .

Synthesis of the pyrimidine moieties of bleomycin and epi-bleomycin

S. Hecht, W. Hagmann, H. Suguna, 1980 .

Synthesis of 3-carboethoxyoxindoles

W. Hagmann, A. Schultz, 1978 .

Synthesis of indole-2-carboxylic esters

W. Hagmann, A. Schultz, 1978 .

Synthesis of β-carbolines from aldehydes and ketones via the α-siloxy α,β-unsaturated esters

M. Reibarkh, R. Nargund, W. Hagmann, 2010 .

Enantioselective approach to 3-substituted prolines

W. Hagmann, T. Kamenecka, L. Lin, 2001 .

Constraining the amide bond in N-sulfonylated dipeptide VLA-4 antagonists.

W. Hagmann, John A. Schmidt, R. Mumford, 2008, Bioorganic & medicinal chemistry letters.

Yue Feng, Donald J. Marsh, Hongbo Qi, 2006, Journal of medicinal chemistry.

Chemistry of 2-substituted pyrimidines. Studies directed toward the synthesis of the pyrimidine moiety of bleomycin

S. Hecht, W. Hagmann, S. Kojo, 1981 .

Characterization of zinc-binding sites in human stromelysin-1: stoichiometry of the catalytic domain and identification of a cysteine ligand in the proenzyme.

J. Hermes, Catherine K. Smith, C. K. Smith, 1992, Biochemistry.

The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes.

Margaret S. Wu, Rebecca T. Ruck, M. Reibarkh, 2012, ACS medicinal chemistry letters.

Rapid Evolution of a Fragment-like Molecule to Pan-Metallo-Beta-Lactamase Inhibitors: Initial Leads toward Clinical Candidates

D. Wyss, A. Therien, T. Fischmann, 2022, Journal of Medicinal Chemistry.

Steroidal glycolipid, L-644,257, is a potent enhancer of nonspecific host resistance.

R. Boltz, W. Hagmann, H. Zweerink, 1990, International Journal of Immunopharmacology.

Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.

F. Ujjainwalla, E. Sherer, A. Howard, 2016, ACS medicinal chemistry letters.

Chapter 21. Potentlal Therapeutic Modifiers of the Complement Cascade

R. Sindelar, W. Hagmann, 1992 .

Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.

M. Maccoss, J. W. Becker, W. Hagmann, 1997, Journal of medicinal chemistry.

Secondary structure and zinc ligation of human recombinant short-form stromelysin by multidimensional heteronuclear NMR.

J. Springer, B. A. Johnson, W. Hagmann, 1993, Biochemistry.

Effects of VLA-4 antagonists in rat whole embryo culture.

W. Hagmann, L. Lin, John A. Schmidt, 2002, Teratology.

SAR exploration at the C-3 position of tetrahydro-β-carboline sstr3 antagonists.

Margaret S. Wu, M. Reibarkh, Yun-ping Zhou, 2016, Bioorganic & medicinal chemistry letters.

Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes

Margaret S. Wu, Yun-ping Zhou, E. Sherer, 2015, ACS medicinal chemistry letters.

VLA‐4 antagonists: Potent inhibitors of lymphocyte migration

W. Hagmann, Ginger X. Yang, 2003, Medicinal research reviews.

Comparative assessment of the ligand and metal ion binding properties of integrins alpha9beta1 and alpha4beta1.

A. Whitty, B. Dolinski, C. Raab, 2002, Biochemistry.

Characterization of alpha(4)beta(1) (CD49d/CD29) on equine leukocytes: potential utility of a potent alpha(4)beta(1) (CD49d/CD29) receptor antagonist in the treatment of equine heaves (recurrent airway obstruction).

D. Thompson, P. Prasit, D. Nicholson, 2009, Veterinary immunology and immunopathology.

Stromelysin‐1: Three‐dimensional structure of the inhibited catalytic domain and of the C‐truncated proenzyme

J. Springer, J. Hermes, P. Fitzgerald, 1995, Protein science : a publication of the Protein Society.

A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation.

W. Hagmann, R. Pepinsky, I. Singer, 2003, American journal of respiratory and critical care medicine.

Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.

W. Hagmann, James P. Jewell, L. Lin, 2009, Bioorganic & medicinal chemistry letters.

1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.

Donald F Thompson, L. Shearman, A. Frassetto, 2009, Journal of medicinal chemistry.

Discovery of N-{(1S,2S)-2-(3-cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical use.

H. Burns, R. Hargreaves, W. Hagmann, 2007, Journal of medicinal chemistry.

A small molecule alpha4beta1/alpha4beta7 antagonist differentiates between the low-affinity states of alpha4beta1 and alpha4beta7: characterization of divalent cation dependence.

S. D. de Laszlo, P. Detmers, C. Raab, 2003, The Journal of pharmacology and experimental therapeutics.

Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.

M. Maccoss, W. Hagmann, K. Lyons, 2002, Bioorganic & medicinal chemistry letters.

Highly constrained bicyclic VLA-4 antagonists.

M. Maccoss, Gail Forrest, W. Hagmann, 2007, Bioorganic & medicinal chemistry letters.

Substituted 3-amino biaryl propionic acids as potent VLA-4 antagonists.

M. Maccoss, W. Hagmann, K. Lyons, 2002, Bioorganic & Medicinal Chemistry Letters.

Adhesion under Shear Flow

S. E. D. Laszlo, B. Pikounis, P. Detmers, 2002 .

Human fibroblast stromelysin catalytic domain: expression, purification, and characterization of a C-terminally truncated form.

H K Chan, J. Hermes, W. Hagmann, 1991, Biochemistry.

Synthesis and cannabinoid-1 receptor binding affinity of conformationally constrained analogs of taranabant.

L. V. D. van der Ploeg, W. Hagmann, James P. Jewell, 2010, Bioorganic & medicinal chemistry letters.

PET Imaging Studies in Rhesus Monkey with the Cannabinoid-1 (CB1) Receptor Ligand [11C]CB-119

Amy Vanko, H. Donald Burns, Christine Ryan, 2009, Molecular Imaging and Biology.

Orally active beta-lactam inhibitors of human leukocyte elastase. 2. Effect of C-4 substitution.

W. Hagmann, A. Maycock, S. K. Shah, 1993, Journal of medicinal chemistry.

The effect of N-acyl substituents on the stability of monocyclic β-lactam inhibitors of human leukocyte elastase

K. R. Thompson, W. Hagmann, A. Maycock, 1992 .

Synthesis and acylation of 2-nitro-11H-dibenzo[b,e][1,4]dioxepin

J. Springer, W. Hagmann, C. Dorn, 1986 .

Synthesis and Acylation of 2-Nitro-11H-dibenzo(b,e)(1,4)dioxepine.

J. Springer, W. Hagmann, C. Dorn, 1987 .

Chemical, biochemical, pharmacokinetic, and biological properties of L-680,833: a potent, orally active monocyclic beta-lactam inhibitor of human polymorphonuclear leukocyte elastase.

K. R. Thompson, W. Hagmann, J. Doherty, 1993, Proceedings of the National Academy of Sciences of the United States of America.

The Asymmetric Transformation of a 1,2-Dihydro-3H-pyrrolo [1,2-a] Pyrrole-1-Carboxylate Ester

W. Hagmann, 1986 .

Design and Synthesis of Novel, Selective GPR40 AgoPAMs.

A. Howard, R. Nargund, W. Hagmann, 2017, ACS Medicinal Chemistry Letters.

The many roles for fluorine in medicinal chemistry.

W. Hagmann, William K. Hagmann, 2008, Journal of medicinal chemistry.

Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N -sulfonylated dipeptide VLA-4 antagonist in rats

R. Evers, T. Baillie, D. Dean, 2008 .

N-(arylacetyl)-biphenylalanines as potent VLA-4 antagonists.

Bing Li, M. Maccoss, S. D. de Laszlo, 2002, Bioorganic & medicinal chemistry letters.

W. Hagmann, James P. Jewell, L. Lin, 2008, Brain Research.

Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N -sulfonylated dipeptide VLA-4 antagonist in rats.

R. Evers, T. Baillie, D. Dean, 2008, Xenobiotica; the fate of foreign compounds in biological systems.

QSAR Prediction of Passive Permeability in the LLC‐PK1 Cell Line: Trends in Molecular Properties and Cross‐Prediction of Caco‐2 Permeabilities

Andreas Verras, Robert P Sheridan, Edward C Sherer, 2012, Molecular informatics.

N-(3-phenylsulfonyl-3-piperidinoyl)-phenylalanine derivatives as potent, selective VLA-4 antagonists.

S. D. de Laszlo, W. Hagmann, T. Kamenecka, 2003, Bioorganic & medicinal chemistry letters.